Innovative Gas Sensors Expand SSB's PAT Portfolio
Sartorius Stedim Biotech (SSB), a leading international supplier of pharmaceutical and biotech equipment, has entered into a global sales partnership with BlueSens, the German experts in gasometric engineering. BlueSens is a highly specialized provider of sensor technology, which is used by the biopharmaceutical industry for inline measurement of gases in microbial fermentation and cell cultivation processes. The co-operation agreement between SSB and BlueSens provides that, alongside BlueSens, SSB will assume global marketing and distribution of its partner company’s oxygen and carbon dioxide sensors, and sell these as private label products under SSB’s brand name BioPAT Xgas.
During the past years, SSB has continuously expanded its process analytics portfolio in the area of sensor technology to measure critical process parameters, such as pH and dissolved oxygen, temperature, glucose, lactate and biomass, non-invasively and in real time. The new oxygen and carbon dioxide sensors are further important additions to SSB’s range of analytical products. BioPAT Xgas enables precise, reproducible information to be obtained about the progress of fermentation, without having to take samples and analyze them off-line in a laboratory.
Stefan Schlack, Senior Vice President of Marketing at SSB, said: "These sensors make our bioreactors even more intelligent. They analyse metabolic processes in real time during cultivation and help our customers better understand their processes. Used in combination with our software, these sensors are powerful tools for optimizing biopharmaceutical production processes and accelerating development."
Dr Holger Müller, Sales and Marketing Manager at BlueSens, stated: “In fermentation, SSB is among the leading suppliers worldwide and has a strong, global sales network. We would like to leverage these advantages to reach considerably more customers. I am looking forward to our partnership.“
BioPAT Xgas will be sold as an equipment package that includes SSB’s single-use and reusable bioreactors. Ready to use right out of the box, the sensors are completely integrated into SSB’s BioPAT DCU control units and SCADA software, called BioPAT MFCS.
In conjunction with Sartorius software, BioPAT Xgas analyses critical process variables, such as oxygen uptake rate (OUR), carbon dioxide production rate (CPR) or respiratory quotient (RQ).
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance